Regeneron Pharmaceuticals (NASDAQ:REGN) PT Raised to $1,200.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target upped by Wells Fargo & Company from $1,125.00 to $1,200.00 in a research note published on Friday, Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently weighed in on REGN. UBS Group increased their target price on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a buy rating in a report on Wednesday, April 17th. StockNews.com cut Regeneron Pharmaceuticals from a strong-buy rating to a buy rating in a report on Tuesday, April 30th. Truist Financial reiterated a buy rating and issued a $1,200.00 price objective (up previously from $1,135.00) on shares of Regeneron Pharmaceuticals in a report on Friday. Piper Sandler increased their price objective on Regeneron Pharmaceuticals from $1,000.00 to $1,166.00 and gave the stock an overweight rating in a report on Friday, July 19th. Finally, Guggenheim raised their target price on Regeneron Pharmaceuticals from $1,040.00 to $1,180.00 and gave the company a buy rating in a research note on Thursday, July 18th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus target price of $1,097.05.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $1,071.28 on Friday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.96. Regeneron Pharmaceuticals has a 52-week low of $765.28 and a 52-week high of $1,115.00. The firm has a market cap of $118.04 billion, a price-to-earnings ratio of 31.65, a PEG ratio of 2.34 and a beta of 0.13. The business’s fifty day moving average is $1,043.43 and its 200 day moving average is $983.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same period in the prior year, the company earned $8.79 EPS. Research analysts predict that Regeneron Pharmaceuticals will post 37.38 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Joseph J. Larosa sold 1,866 shares of the firm’s stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the transaction, the executive vice president now directly owns 37,937 shares in the company, valued at approximately $41,311,496.15. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the transaction, the director now directly owns 17,882 shares in the company, valued at approximately $18,941,329.68. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Joseph J. Larosa sold 1,866 shares of the firm’s stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the completion of the transaction, the executive vice president now owns 37,937 shares in the company, valued at $41,311,496.15. The disclosure for this sale can be found here. In the last quarter, insiders sold 65,074 shares of company stock valued at $64,546,123. Corporate insiders own 7.48% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of REGN. Norges Bank purchased a new position in Regeneron Pharmaceuticals during the fourth quarter valued at $932,571,000. Global Assets Advisory LLC purchased a new position in Regeneron Pharmaceuticals during the first quarter valued at $339,594,000. Capital International Investors lifted its position in Regeneron Pharmaceuticals by 7.3% during the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after purchasing an additional 213,038 shares in the last quarter. First Trust Advisors LP lifted its position in Regeneron Pharmaceuticals by 115.2% during the fourth quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock valued at $321,410,000 after purchasing an additional 195,902 shares in the last quarter. Finally, abrdn plc lifted its position in shares of Regeneron Pharmaceuticals by 552.8% in the fourth quarter. abrdn plc now owns 219,900 shares of the biopharmaceutical company’s stock valued at $193,136,000 after acquiring an additional 186,215 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.